As many as 40% of U.S. narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers, according to a study Express Scripts presented Monday at AcademyHealth's annual research meeting.
The Office of the National Coordinator for Health Information Technology last week issued a policy paper, "A 10-Year Vision to Achieve an Interoperable Health IT Infrastructure," which outlines the government's pledge to support interoperable electronic health records to most Americans.
A report published Friday in the Morbidity and Mortality Weekly Report characterized the 2013-2014 influenza season as the first season since 2009 that H1N1 generated fewer levels of outpatient illness and mortality as compared with seasons when influenza A (H3N2) is predominant.
The Centers for Disease Control and Prevention recently updated a health advisory, recommending an inactivated poliovirus booster for adults traveling to countries with an active wild polio virus in circulation.
Health Media Network and the American College of Cardiology on Wednesday announced a strategic partnership that will significantly increase the size of HMN's Cardiology Network while broadening the distribution of ACC's CardioSmart Initiative.
Upsher-Smith Laboratories on Wednesday announced that it has received final approval from the Food and Drug Administration for its new drug application for Vogelxo (testosterone) gel for topical use CIII.
Asana BioSciences, a research and development company specializing in the discovery and development of new chemical and biological entities, on Tuesday announced that it has acquired an early stage branded pharmaceutical discovery platform from Endo Pharmaceuticals.
HDMA on Tuesday honored pharmaceutical and consumer product manufacturers at its 2014 Business and Leadership Conference in Phoenix, through the presentation of the Association’s annual Distribution Industry Awards for Notable Achievements in Healthcare (the DIANA awards).
Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.
Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.
Indian drug maker Wockhardt has been charged by the Food and Drug Administration with utilizing the same unapproved method to test drug quality in its Morton Grove, Ill., facility as two facilities in India, both of which were subsequently banned from importing into the United States,the Wall Street Journal reported Tuesday.
Mission Pharmacal on Thursday announced that it has begun the promotion of Elestrin (estradiol gel) 0.06% in the United States through an agreement with Meda AB. The drug is a used as a topical hormone replacement gel to help treat hot flashes caused by menopause.
Trimel Pharmaceuticals on Wednesday announced that the Food and Drug Administration has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
There may be a connection between taking vasodilators and developing early-stage, age-related macular degeneration, the leading cause of vision loss and blindness among Americans who are ages 65 and older, according to a study published online Wednesday in Ophthalmology, the journal of the American Academy of Ophthalmology.
Despite clear evidence of ineffectiveness, guidelines and more than 15 years of educational efforts stating that the antibiotic prescribing rate for acute bronchitis should be zero, the rate was about 70% from 1996 to 2010 and increased during this time period, according to a study in the May 21 issue of JAMA.
Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.